Lapatinib and cisplatin synergise in suppression of head and neck squamous cell carcinoma ex vivo

Gunnar Wichmann, Christoph Schrader, Pierre Kruber, Andreas Dietz, Anett Reiche, Grit Müller, Iris-Susanne Horn, Christian Mozet & Andreas Boehm
Introduction: The tyrosine-kinase inhibitor (TKI) lapatinib is introduced into multimodal therapy of advanced head and neck squamous cell carcinoma (HNSCC). Purpose: To analyze the dose-response curve of lapatinib and whether this TKI combined with cisplatin exerts synergistic suppressive effects[for full text, please go to the a.m. URL]